RegulatoryBusinessLine
Natco Pharma gets USFDA EIR for Visakhapatnam plant
Negative-322 sources
GreyOak summary
Natco Pharma received an Establishment Inspection Report (EIR) from the US FDA regarding its FDF manufacturing plant in Parawada, Visakhapatnam. The inspection, conducted between August 17 and 21, 2026, resulted in four observations listed in Form-483. The FDA classified the inspection findings as Voluntary Action Indicated (VAI).
What it affects
- Natco PharmaNATCOPHARMNegative -32
Received USFDA EIR with four observations.Rolling sentiment Negative -34
Source
Reported by BusinessLine
- Business Today
- BusinessLine
More Natco Pharma news
- Natco Pharma receives EIR from US FDA for Visakhapatnam plantCNBC-TV18 · Company update ·
- Buy Natco Pharma: target of Rs 1065: ICICI SecuritiesMoneycontrol · Company update ·
- Natco Pharma shares rally 9% despite weak Q2 resultsNDTV Profit · Results ·
- Natco Pharma Q2 profit drops 60.8% to ₹202.6 crBusiness Standard · Results ·
- Natco Pharma Q2 profit, revenue fall; dividend declaredCNBC-TV18 · Results ·